title: High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon.
authors.forename: Mir
authors.initials: M
authors.lastname: Alikhan
authors.forename: Horace J
authors.initials: HJ
authors.lastname: Spencer
authors.forename: Manish
authors.initials: M
authors.lastname: Kohli
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009392:Nephrectomy; D018579:Patient Selection; D011379:Prognosis; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins